Today, AI Pharmaceutical UnicorninsitroAndBristol-Myers Squibb(BMS) today announced that the two parties will carry out the next phase of cooperation to discover new molecules with the potential to become new therapies for amyotrophic lateral sclerosis (ALS).
This collaboration extension will leverage insitro's artificial intelligence. ChemML™ The platform designs new drugs for novel ALS targets identified in the first biological evaluation phase and may provide up to a one-year extension.$20 millionNew funding.
In addition to royalties, the total value of payments to insitro Inc. for the successful delivery of new therapies under this collaboration could exceed those linked to discovery, development, regulatory, and commercial milestones.$2 billion。
As early as2020 In that year, the company collaborated with Bristol-Myers Squibb.(BMS) Signed an agreement to discover Amyotrophic Lateral Sclerosis(ALS) The new therapy - as part of this agreement,insitroLast year12Month obtained2500Million USDMilestone payments for achieving discovery milestones and selectionALS The first new target.Insitro was founded in 2018, and its founder and CEO is a computational scientist hailed as a genius.Daphne Koller（ Daphne Koller ）。As a serial entrepreneur, Daphne Koller once co-founded insitro Inc. with another top expert in the artificial intelligence field, Andrew Ng.Online EducationEnterpriseCoursera。February 2018,Daphne KollerEstablishedAI Drug Discovery Company insitroIn May 2018, the company completed a $100 million Series A round of financing.In April 2019, completed a US$100 million Series A+ financing round, and in May 2020, completed a US$143 million Series B financing round,2021 Completed$400 millionC Round Financing。To date,insitroCumulative financing up to$743 million(Approximately RMB 5.3 billion), becoming one of the companies with the highest financing in the AI + drug research and development track.insitro To date, multiple partnerships have been established.2018 Shortly after its establishment in the year, the company collaborated with Gilead Sciences.Established a partnership to discover and develop treatments for non-alcoholic steatohepatitis (NASH).(NASH) New therapy.Recently,insitroWithEli LillyCooperation, according toinsitro Using the company's basedAI/ML The platform-identified targets advance new therapies for metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH).(MASLD)。—END—
